bearish
Paradigm Biopharmaceuticals (PAR AU): Concerns Persist Amid Deteriorating Financials
229 Views14 Mar 2022 21:36
SUMMARY
- Paradigm Biopharmaceuticals (PAR AU) shares plunged 32% since we published our bearish insight on the company on January 11. Shares are trading near their pandemic lows.
- Our negative view on the company due to the inherent safety proposition of lead drug and financial uncertainty remain intact. Insider buying led to the recent uptick in share prices.
- Amid uncertain global market condition and general market apathy toward biotechnology companies, we will not be an investor of Paradigm Biopharmaceuticals despite its recent sell-down.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Paradigm Biopharmaceuticals (PAR AU): Positive Result from Phase 2 Trial; Satisfactory Cash Position18 Oct 2023
- Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 202417 Aug 2022
- Paradigm Biopharmaceuticals (PAR AU): Concerns Persist Amid Deteriorating Financials14 Mar 2022
- Paradigm Biopharmaceuticals (PAR AU): Concerns on First Potentially Commercialized Product11 Jan 2022
x